Anti-hepatitis A seroprevalence among chronic viral hepatitis patients in Kelantan, Malaysia
| Autor: | Siew Hua Gan, Nazri Mustaffa, Fazlina Ahmad, Nor Aizal Che Hamzah |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Adult
Male medicine.medical_specialty congenital hereditary and neonatal diseases and abnormalities Cirrhosis Brief Article viruses Hepatitis A vaccine Chronic liver disease Hepatitis A Antibodies Young Adult Seroepidemiologic Studies Internal medicine medicine Seroprevalence Humans Aged Hepatitis Chronic Hepatitis A Vaccines business.industry Gastroenterology Malaysia Hepatitis A General Medicine Hepatitis C Hepatitis B Middle Aged medicine.disease respiratory tract diseases Immunology Female Viral hepatitis business |
| Zdroj: | World journal of gastroenterology. 17(36) |
| ISSN: | 2219-2840 |
| Popis: | AIM: To determine the seroprevalence of anti-hepatitis A virus (HAV) antibodies in patients with chronic liver disease (CLD) and to justify the need for hepatitis A vaccination. METHODS: Patients (n = 119) were enrolled between July and September 2009. The diagnosis of CLD was based on the presence of viral markers for more than 6 mo. The diagnosis of liver cirrhosis was based on clinical, biochemical and radiological profiles. Patient serum was tested for anti-HAV IgG. RESULTS: The overall anti-HAV seroprevalence was 88.2%. The aetiology of CLD was hepatitis B in 96 patients (80.7%) and hepatitis C in 23 patients (19.3%). Mean age was 44.4 ± 14 years. Patients were grouped according to age as follows: 24 (20.2%) patients in the 21-30 years age group, 22 (18.5%) in the 31-40 years age group, 31 (26.1%) in the 41-50 years age group, 23 (19.3%) in the 51-60 years age group and 19 (16.0%) patients aged greater than 60 years, with reported seroprevalences of 66.7%, 95.5%, 93.5%, 91.3% and 94.7%, respectively. There was a marked increase of seroprevalence in subjects older than 30 years (P = 0.001). CONCLUSION: Our study demonstrated that patients aged greater than 30 years of age were likely to have natural immunity to hepatitis A. Therefore, hepatitis A vaccination may not be routinely required in this age group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|